Shares of drug developer Xilio Therapeutics XLO.O rise 3.18% to $8.11 premarket
Co posts Q4 profit of 81 cents per share, while analysts were expecting loss of $1.68 per share - data compiled by LSEG
Posts Q4 revenue of $13.7 million vs estimate of $7.9 million
Says quarterly revenue rose on higher collaboration and license revenue, driven by its AbbVie collaboration and Gilead license agreement
XLO shares were down over 32% in 2025